AKRO ANNOUNCEMENT: If You Have Suffered Losses in Akero Therapeutics, Inc. (NASDAQ: AKRO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, June 16, 2024 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023, both dates inclusive (the “Class Period”), shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 12, 2024.

If you purchased Akero common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

To join the Akero class action, go to https://rosenlegal.com/submit-form/?case_id=24557 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 25, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors.

Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) approximately 20% of the patients enrolled in the SYMMETRY study, a trial that purportedly tested its  lead product candidate, efruxifermin (“EFX”) in patients with Non-alcoholic Steatohepatitis (“NASH”) induced cirrhosis, had cryptogenic cirrhosis and did not have definitive NASH at baseline; (2) the cryptogenic cirrhotic patients included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis due to definitive NASH; (3) the results from the cryptogenic cirrhosis patients were to be excluded from the calculation of the NASH resolution secondary endpoints; (4) Akero had introduced a confounding factor into the SYMMETRY study’s design, materially influencing the study’s potential results and increasing the risks that the study would fail to meet its primary endpoint; (5) the SYMMETRY study did not align with U.S. Food & Drug Administration guidance for testing a drug in treating NASH cirrhotics because Akero had not ruled out potential causes of each patient’s cirrhosis other than NASH; and (6) consequently, Akero had materially misrepresented the nature of the SYMMETRY trial, its usefulness in supporting any new drug application, the likelihood that the SYMMETRY trial would be successful as measured by its primary endpoint, and the likelihood EFX would become a commercial treatment for NASH cirrhotics. When the true details entered the market, the lawsuit claims that investors suffered damages.

What Now: You may be eligible to participate in the class action against Akero Therapeutics. The deadline to file a motion to be appointed as lead plaintiff is August 12, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, go to https://rosenlegal.com/submit-form/?case_id=24557.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 9154577

RBLX INVESTOR NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Roblox Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – RBLX

NEW YORK, June 16, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Roblox Corporation (NYSE: RBLX) between November 15, 2023 and May 8, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 12, 2024.

SO WHAT: If you purchased Roblox securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Roblox class action, go to https://rosenlegal.com/submit-form/?case_id=25991 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 12, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or created the false impression that they possessed reliable information pertaining to Roblox’s projected revenue outlook and anticipated bookings growth, due largely to expansions in Roblox’s available platforms, changes in Roblox’s digital technology (such as avatars), Roblox’s shared economy with content creators, and advertising revenue. In truth, Roblox knew each of those bookings and revenue sources were tenuous at best. In fact, Roblox faced difficulty converting daily average users (“DAUs”) into bookings and eventually blamed the very technology and platform growth it lauded as revolutionary and revenue-generating for this bookings problem. Defendants misled investors by providing the public with a materially flawed outlook for the relationship between DAU, bookings, and technology it lauded during its Investor Day and Earnings Call. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Roblox class action, go to https://rosenlegal.com/submit-form/?case_id=25991 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 9154394

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS

NEW YORK, June 16, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) between March 17, 2021 and May 7, 2024, both dates inclusive (the “Class Period”), of the important August 5, 2024 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased Marinus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Marinus class action, go to https://rosenlegal.com/submit-form/?case_id=25735 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 5, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) defendants understated the risk of failure to meet the early-stopping criteria in the RAISE trial; (2) defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Marinus class action, go to https://rosenlegal.com/submit-form/?case_id=25735 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 9154384

From Awareness to Action on Global Fatty Liver Day

Global Liver Institute Unites the Field in Times of Name Changes and New Treatments

WASHINGTON, June 13, 2024 (GLOBE NEWSWIRE) — Today marks the seventh annual Global Fatty Liver Day (formerly International NASH Day), led by Global Liver Institute (GLI) with the theme “Act Now, Screen Today.” This campaign underscores the crucial need for early identification and treatment of fatty liver disease to prevent its progression to chronic liver disease, cirrhosis, or cancer.

Fatty liver disease is now estimated to affect 1 in 3 adults worldwide, and its prevalence is increasing. Fatty liver disease during childhood, once unheard of, is also on the rise. Early detection and timely intervention, whether through lifestyle changes or medical treatments, are essential in stopping and even reversing the progression of the disease. “Act Now, Screen Today” emphasizes that liver health is achievable, but action must begin immediately. Across the globe, partners are driving awareness and educational efforts and ensuring broader access to essential screenings and care.

Global Fatty Liver Day, observed annually on the second Thursday of June, is a rallying cry for collective action to address the growing prevalence of fatty liver disease, the most common liver disease worldwide. “Act Now, Screen Today” reminds everyone that liver health is within reach. Here are specific actions you can take today:

  • Take advantage of liver health screening events happening globally to get assessed for fatty liver disease or schedule a check-up with your doctor, especially if you are managing closely associated metabolic conditions like obesity or diabetes
  • Increase physical activity, as maintaining an active lifestyle can improve liver health
  • Learn about fatty liver disease and its risk factors to take proactive steps towards prevention and management yourself or learn more about the latest research and guidelines for your patients.

With a robust pipeline of pharmaceutical treatments that address diverse mechanisms of action in progress, it is important to identify individuals’ position within the progression of fatty liver disease so that they are poised to receive the most appropriate care possible. Notably, pharmaceutical treatments are available (for certain groups with advanced disease) in two countries, the United States (resmetirom) and India (saroglitazar).

“As a community, we stand at a critical time for the broader global health system to act now to support patients,” shares Donna R. Cryer, JD, Founder and CEO of GLI. “As pharmaceutical treatment options gain approval in different geographies, health payers and systems must listen to the call from global advocates and not place undue obstacles to care – whether that be required biopsy, ambiguous lifestyle requirements, or other hurdles – so that patients are able to access the care they require, no matter who or where they are.”

Recognizing the importance of early detection, a diverse range of partners, including healthcare providers, patient advocacy groups, and community organizations, have joined forces to “Act Now, Screen Today” and launch screening events around the world. From Chile to Nigeria to the Netherlands, the Philippines, and beyond, these events aim to raise awareness, provide education, and offer screening services to individuals at risk of fatty liver disease or the providers who care for them. Global Fatty Liver Day activities are driving positive change at the grassroots level.

“Global Fatty Liver Day is an urgent call-to-action to unite our global efforts to confront the scourge of fatty liver disease,” shares Cat Evans, Director of Program Operations at GLI. “We must act now. By working together, we have the power to create significant change in preventing and managing this pressing health issue through our collaborative efforts.”

Although the challenge of fatty liver disease to the well-being of communities around the globe is great, the power of locally-rooted, collective efforts can turn the tide towards positive change by heightening awareness, equipping people and their healthcare providers with prevention and management tools, expanding understanding of the disease through research, and protecting future liver health through effective policies.

About Global Liver Institute

Global Liver Institute (GLI) is a 501(c)3 nonprofit organization founded in the belief that liver health must take its place on the global public health agenda commensurate with the prevalence and impact of liver illness. GLI promotes innovation, encourages collaboration, and supports the scaling of optimal approaches to help eradicate liver diseases. Operating globally, GLI is committed to solving the problems that matter to liver patients and equipping advocates to improve the lives of individuals and families impacted by liver disease. Follow GLI on FacebookInstagramLinkedIn, and YouTube, or visit www.globalliver.org. GLI is the host of Global Fatty Liver Day.

Christine Maalouf
Global Liver Institute
cmaalouf@globalliver.org

GlobeNewswire Distribution ID 9153607

Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen

ADALVO LIMITED
Anil Okay, Adalvo CEO, expresses his thoughts on this milestone

SAN ĠWANN, Malta, June 13, 2024 (GLOBE NEWSWIRE) — Adalvo announces the successful DCP approval for Liraglutide pre-filled pen, marking it as the first generic approval in the EU.

As a bioequivalent version of Victoza® pre-filled pen, indicated for the treatment of type 2 diabetes, this peptide drug achieved global sales exceeding $4.8 billion in 2023, as reported by IQVIA.

The successful development of Liraglutide highlights Adalvo’s capability to offer a diverse and comprehensive diabetes portfolio, encompassing both complex peptide injectables and small molecule oral treatments.

Adalvo’s commitment to providing access to high-quality differentiated products while simultaneously navigating manufacturing complexities reinforces Adalvo’s position as a trusted leader in the pharmaceutical industry.

Click Here To View Adalvo’s Diabetes Portfolio

At Adalvo, there are no half-measures – they are always on target. Their mission is to be faster and stronger than their competitors, driving their vision forward with a winning team.

Adalvo is committed to maintaining the highest standards of excellence in all their endeavors and looks forward to continuing to deliver innovative healthcare solutions that make a difference in the lives of patients worldwide.

About Adalvo

Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 130 countries and over 140 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering the highest quality differentiated products and services to our partners.

Adalvo takes pride in their ability to help partners reach their goals – be those increasing revenues or pushing into new markets. Tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion for making a difference for partners.

The company’s purpose-driven culture is committed to improving the lives of patients around the world. Adalvo’s dynamic leadership team brings significant experience and industry know-how, which has helped to establish the company as a reliable global partner in the industry.

Contacts: Gabrielle Cassar, gabrielle.cassar@adalvo.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e1e895aa-f689-4215-a1f8-25285851af9d

GlobeNewswire Distribution ID 1000966220

Nikkiso Clean Energy & Industrial Gases Group Announces CEO Transition July 1, 2024

TEMECULA, Calif., June 13, 2024 (GLOBE NEWSWIRE) — Nikkiso Co., Ltd. (TSE: 6376), announced today after a Board vote, that effective July 1, 2024, Adrian Ridge will succeed Peter Wagner as Nikkiso Clean Energy & Industrial Gases Group’s (part of Nikkiso’s Industrial Division) as Chief Executive Officer. Wagner will stay on in a Board role as Executive Chairman for Nikkiso CE&IG Group.

As CEO, Ridge, who is currently Executive Vice President, Operations and Manufacturing for Nikkiso CE&IG Group, will drive operational and financial results and ready the Group for future growth. Wagner’s new role as Executive Chairman will focus on driving the vision and long-term strategy of the Group in an advisor capacity.

“In six years under Peter’s leadership, Nikkiso CE&IG has more than quadrupled business, and is positioned for strong continued growth,” said Toshihiko Kai, President and CEO, Nikkiso. “I want to thank him for his leadership, and welcome Adrian as the Group’s new CEO.”

Prior to joining Nikkiso in 2018, Wagner was CEO and Managing Director at LEWA Group. Ridge joined Nikkiso in 2022 after approximately 30 years at Atlas Copco serving in various leadership positions.

About Nikkiso Co. Ltd.

Since its establishment in 1953, Nikkiso has contributed to solving social issues by anticipating the changing times with world-first and Japan-first technologies and products. In the industrial business, Nikkiso has created new markets by developing products in the energy field, hemodialysis-related products in the medical business, and CFRP (carbon fiber reinforced plastic) aerostructures in the aerospace business.

About Nikkiso Clean Energy & Industrial Gases Group

The Nikkiso Clean Energy & Industrial Gases Group is a leading provider of cryogenic equipment, technologies and applications for clean energy and industrial gas market segments. The Group employs more than 1,600 people in 22 countries and is headed by Cryogenic Industries, Inc. in Southern California, U.S., which is a wholly owned subsidiary of Nikkiso Co., Ltd. (TSE: 6376).

Media contact
Lisa Adams
+1 405 492 1689

GlobeNewswire Distribution ID 9153273

‫منصة إكس ترانسفير وبنك بانكنج سيركل يعلنان شراكة استراتيجية

شراكة من المقرر أن تعزز إمكانيات الدفع للواردات/الصادرات في أوروبا والشرق الأوسط

المنطقة الإدارية الخاصة في هونغ كونغ، 11 يونيو 2024 – ثمة شراكة استراتيجية قد عُقدت بين منصة إكس ترانسفير، المنصة الأولى في الصين والرائدة على مستوى العالم لمدفوعات التجارة العابرة للحدود بين الشركات؛ وبنك بانكنج سيركل، بنك المدفوعات المبنية على التكنولوجيا المبتكرة. ويهدف هذا التعاون إلى تقليل تكلفة ووقت معالجة المدفوعات العابرة للحدود لصالح عملاء إكس ترانسفير، وخصوصًا إفادة الموردين الصينيين من الأسواق الكبيرة في أوروبا والشرق الأوسط.

يُعد كل من منصة إكس ترانسفير وبنك بانكنج سيركل ملتزمان بتقليل التكلفة المرتبطة بمدفوعات التجارة العالمية. وتركز إكس ترانسفير على تزويد الشركات الصغيرة والمتوسطة بحلول دفع وتحصيل أموال عابرة للحدود ومعقولة التكلفة وسريعة ومتوافقة وآمنة، مما يعزز من التنافس العالمي ويسهل التوسع الدولي. أنشأ بنك بانكنج سيركل شبكة مقاصة محلية شاملة للعملات الرئيسية ومحرك عملات أجنبية فعال يدعم 24 عملة، مما يوفر مدفوعات سريعة وقليلة التكلفة دون رسوم مخفية.

ومن خلال تكامل البنية الأساسية لبنك بانكنج سيركل، تستطيع إكس ترانسفير الآن أن تقدم لعملائها مجموعة واسعة من خيارات الدفع وتحصيل الأموال المحلية. وسيكون العملاء قادرين على تلقي المدفوعات ليس فقط بالعملات الرئيسية مثل الدولار الأمريكي واليورو والجنيه الاسترليني والكرونة الدنماركية، ولكن أيضًا بست عملات إضافية في أوروبا والشرق الأوسط. ومن المتوقع أن تتوسع هذه الشراكة بشكل أكبر، مع وجود خطط لتقديم المزيد من خيارات العملات في المستقبل القريب.

وهذا التطور مفيد بشكل خاص للشركات التي تتعامل مع الموردين الصينيين. وسيتمتع المشترون في أوروبا والشرق الأوسط بسهولة الدفع للموردين الصينيين بمجموعة واسعة من العملات المحلية.

وتعليقًا على الشراكة؛ صرح بيل دينج، المؤسس والرئيس التنفيذي لشركة إكس ترانسفير، قائلاً: “يمثل تعاوننا مع بنك بانكنج سيركل خطوة مهمة نحو الأمام في طريقنا للتوسع في الأسواق الأوروبية والشرق أوسطية. ولا يقتصر دور هذه الشراكة على تسريع الطموحات العالمية لشركة إكس ترانسفير فحسب، بل تقدم وعدًا أيضًا بإحداث ثورة في مشهد التجارة الدولية للشركات. ونحرص دائمًا على رؤية النجاح المستمر لهذا التعاون.”

أضاف لاوست بيرتيلسن، المؤسس المشارك والرئيس التنفيذي لبنك بانكنج سيركل، قائلاً: “يسعدنا دعم رؤية إكس ترانسفير للتجارة العالمية. ومن خلال الاستفادة من حسابات بانكنج سيركل وأنظمة الدفع، يمكن لشركة إكس ترانسفير تبسيط عملية الدفع لعملائها، مما يقلل من التكاليف ومن أوقات المعاملات.”

إكس ترانسفير

إكس ترانسفير، منصة الدفع للتجارة العابرة للحدود بين الشركات والتي تشغل المرتبة الأولى في الصين، مكرسة لتزويد الشركات الصغيرة والمتوسطة بحلول دفع وتحصيل أموال للتجارة الخارجية، والتي تكون آمنة ومتوافقة وسريعة ومريحة ومنخفضة التكلفة، مما يقلل بشكل كبير من تكلفة التوسع العالمي ويعزز التنافسية العالمية. وقد تأسست الشركة في عام 2017، ويقع المقر الرئيسي للشركة في شنغهاي، ولها فروع في هونغ كونغ والمملكة المتحدة وهولندا والولايات المتحدة وكندا واليابان وأستراليا وسنغافورة. حصلت إكس ترانسفير على تراخيص للمدفوعات المحلية في هونغ كونغ والمملكة المتحدة والولايات المتحدة وكندا وأستراليا. وأصبحت إكس ترانسفير الصناعة رقم 1 في الصين بما لديها من أكثر من 450,000 عميل من عملاء المؤسسات.

من خلال التعاون مع البنوك والمؤسسات المالية متعددة الجنسيات المعروفة، قامت إكس ترانسفير ببناء شبكة مقاصة عالمية موحدة متعددة العملات وأنشأت بنية أساسية ذكية ومؤتمتة ومعتمدة على البيانات ومعتمدة على الإنترنت ومكافحة لمخاطر غسيل الأموال تتمحور حول المؤسسات الصغيرة والمتوسطة. تستخدم إكس ترانسفير التكنولوجيا كجسر لربط المؤسسات المالية الكبيرة والمؤسسات الصغيرة والمتوسطة حول العالم، مما يسمح للشركات الصغيرة والمتوسطة بالاستمتاع بنفس مستوى الخدمات المالية العابرة الحدود مثل الشركات الكبيرة متعددة الجنسيات.

أكملت إكس ترانسفير تمويلها من السلسلة “د” في سبتمبر 2021، وحققت مكانة وحيد القرن. تمتلك الشركة تشكيلة متنوعة من المستثمرين الدوليين، بما في ذلك D1 Capital Partners LP، وTelstra Ventures، وChina Merchants Venture، وeWTP Capital، وYunqi Capital، وGaorong Capital، و01VC، وMindWorks، وLavender Hill Capital Partners.

لمزيد من المعلومات: https://www.xtransfer.com/

 بانكنج سيركل ش.م

بانكنج سيركل هو بنك المدفوعات للاقتصاد الجديد. وباعتباره بنكًا مرخصًا بالكامل وخاليًا من الأنظمة القديمة، فإن بنك بانكنج سيركل يُمكّن شركات المدفوعات والبنوك من أي حجم من اغتنام الفرص في الاقتصاد الجديد – وذلك بوتيرة سريعة وبتكلفة منخفضة.

بانكنج سيركل ش.م هو بنك متوافق وحديث ملتزم ببناء شبكة مقاصة محلية لجميع العملات الرئيسية، لتقديم مدفوعات سريعة ومنخفضة التكلفة دون أي رسوم خفية للمستفيد. وهو يوفر مجموعة من الحلول المصرفية الفريدة والحائزة على جوائز، بما في ذلك الحسابات المصرفية متعددة العملات، وأرقام الآيبان الافتراضية، والاتصالات المصرفية للمقاصة المحلية، والمدفوعات عبر الحدود، وكلها مدعومة بالامتثال والأمن الرائدين في السوق.

من خلال حلول مخصصة ومرنة وقابلة للتطوير ومواكبة للمستقبل، يعمل بانكنج سيركل ش.م على تمكين المؤسسات المالية من مساعدة عملائها على إجراء المعاملات عبر الحدود بطريقة لم تكن ممكنة في السابق.

يقع المقر الرئيسي لبنك بانكنج سيركل في لوكسمبورغ، وله مكاتب في لندن وميونيخ وكوبنهاغن.

XTransfer and Banking Circle Announce Strategic Partnership

Collaboration Set to Boost Payment Capabilities for Importers/Exporters  in Europe and the Middle East

HONG KONG SAR – Media OutReach Newswire – 11 June 2024 – XTransfer, the World’s Leading & China’s No.1 B2B Cross-Border Trade Payment Platform, and Banking Circle, the innovative tech-driven Payments Bank, have entered into a strategic partnership. This collaboration aims to reduce the cost and processing time of cross-border payments for XTransfer’s clients, particularly benefiting Chinese suppliers with significant markets in Europe and the Middle East.

Both XTransfer and Banking Circle are committed to minimising the cost associated with global trade payments. XTransfer focuses on providing SMEs with secure, compliant, fast, and cost-effective cross-border payment and fund collection solutions, thereby enhancing global competitiveness and facilitating international expansion. Banking Circle has established a comprehensive local clearing network for major currencies and an effective FX engine supporting 24 currencies, ensuring quick, low-cost payments without hidden fees.

Through the integration of Banking Circle’s infrastructure, XTransfer can now offer its clients a broader array of local payment and fund collection options. Clients will be able to receive payments not only in major currencies like the US Dollar, Euro, GBP, and Danish Krone, but also in six additional currencies in Europe and the Middle East. This partnership is expected to expand further, with plans to introduce even more currency options in the near future.

This development is particularly advantageous for businesses dealing with Chinese suppliers. Buyers in Europe and the Middle East will have the convenience of paying Chinese suppliers in a wider range of local currencies.

Bill Deng, Founder and CEO of XTransfer, commented on the partnership, “Our alliance with Banking Circle represents a significant step forward in our expansion into the European and Middle Eastern markets. This partnership not only accelerates XTransfer’s global ambitions but also promises to revolutionise the international trade landscape for businesses. We are eager to see the continued success of this collaboration.”

Laust Bertelsen, Co-Founder and CEO of Banking Circle added, “We are thrilled to support XTransfer’s vision for global trade. By leveraging Banking Circle’s accounts and payment rails, XTransfer can streamline the payment process for its clients, reducing both costs and transaction times.”

XTransfer

XTransfer, World’s Leading & China’s No.1 B2B Cross-Border Trade Payment Platform, is dedicated to providing SMEs with secure, compliant, fast, convenient and low-cost foreign trade payment & fund collection solutions, significantly reducing the cost of global expansion and enhancing global competitiveness. Founded in 2017, the company is headquartered in Shanghai and has branches in Hong Kong, the United Kingdom, the Netherlands, the United States, Canada, Japan, Australia, and Singapore. XTransfer has obtained local payment licenses in Hong Kong, the United Kingdom, the United States, Canada, and Australia. With more than 450,000 enterprise clients, XTransfer has become the industry No.1 in China.

By cooperating with well-known multinational banks and financial institutions, XTransfer has built a unified global multi-currency clearing network and built a data-based, automated, Internet-based and intelligent anti-money laundering risk control infrastructure centred on small and medium enterprises. XTransfer uses technology as a bridge to link large financial institutions and small and medium enterprises around the world, allowing SMEs to enjoy the same level of cross-border financial services as large multinational corporations.

XTransfer completed its Series D financing in September 2021 and achieved unicorn status. The Company possesses a diverse composition of international investors, including D1 Capital Partners LP, Telstra Ventures, China Merchants Venture, eWTP Capital, Yunqi Capital, Gaorong Capital, 01VC, MindWorks and Lavender Hill Capital Partners.

For more information: https://www.xtransfer.com/

Jollibee Named Among Top 10 Brands in Kuwait for Customer Satisfaction

KUWAIT CITY, KUWAIT – Media OutReach Newswire – 11 June 2024 – Beloved restaurant brand Jollibee has been recognized as one of the Top 10 Brands for Customer Satisfaction in Kuwait by the 2023 Service Hero Customer Satisfaction Index (CSI) Awards.

Warm, joyful service. Jollibee earned another triumph with its recent inclusion in the Top 10 brands for customer satisfaction in Kuwait. The awards program by Service Hero surveyed over 500 brands in the country.

The Service Hero CSI Awards honors companies in Kuwait that deliver exceptional customer service, measuring key factors such as expectations, satisfaction, and likelihood of recommendation. It also measures different service dimensions such as staff, location, product quality, value for money, speed, and reliability. Over 500 brands across 20 categories were surveyed.

“Being recognized among Kuwait’s Top 10 brands for customer satisfaction from over 500 brands is a testament to our commitment to providing customers with great-tasting food served with the warmth and joyful service that the Jollibee brand is known for. This citation is not only a badge of honor for us, but it also means we are fulfilling our promise to our customers,” said Joseph Tanbuntiong, Jollibee Group Chief Business Officer and Head, Jollibee Global.

Serving joy. The Jollibee Kuwait team has shown passion and dedication in providing exceptional customer service to customers who crave for bestsellers Chickenjoy and Jolly Spaghetti.

Dennis Flores, President of Jollibee Group’s business in Europe, Middle East, and Asia, and Australia (EMEAA), congratulated the Jollibee Kuwait team and franchisee for the milestone: “We celebrate this achievement with all our store and operations teams in Kuwait whose passion and dedication to our mission of serving great-tasting food and bringing the joy of eating to everyone has made this recognition possible. We are also grateful to our customers in Kuwait for their continued support and loyalty to Jollibee.”

Flores added, “We extend our deepest gratitude to our franchisee Yacoub Aljajery for his steadfast belief in our brand. His hands-on approach not only ensures operational excellence, but also fosters a culture of passion and commitment, making exceptional customer service at Jollibee Kuwait possible.”

The Jollibee Group opened the first Jollibee store in Al Watya, Kuwait City in February 2012 through franchisee Yacoub Aljajery of the Al Musaifra Catering Company. Today, Jollibee has seven stores in Kuwait, with loyal fans craving for bestselling products like Chickenjoy and Jolly Spaghetti.

Jollibee as a franchisor of choice

Aljajery highlighted the factors behind Jollibee’s success in Kuwait, including its strong brand recognition and comprehensive support system. “I chose Jollibee as a franchise because of its strong brand recognition, delicious menu offerings, and the opportunity to introduce Jollibee to Arab/Kuwaiti customers, which has proven to be a successful venture,” said franchisee Aljajery. “I appreciate Jollibee’s comprehensive support system, including marketing assistance, ongoing operational guidance, and training programs which have been instrumental in the growth and success of our franchise operations in Kuwait.

He added, “Being cited as one of the Top 10 brands in Kuwait is a recognition of our dedication and hard work in upholding Jollibee’s standards and values. This award also serves as our source of pride and motivation to continue delivering exceptional service and quality to our customers in Kuwait.”

Jollibee also has stores in other Middle East countries such as the United Arab Emirates (UAE), Kingdom of Saudi Arabia, Qatar, Bahrain, and Oman.

Global recognition and growth

Recently, Jollibee has been ranked Top 5 Strongest Restaurant Brand in the World, overtaking more established Quick Service Restaurant brands, according to the latest annual brand ranking report by Brand Finance, the world’s leading independent brand valuation agency. Jollibee has elevated its rating from AA- to AAA. In addition, Jollibee is the only Philippine brand listed in the 2024 Top 25 Most Valuable Restaurant Brands and Top 10 Strongest Restaurant Brands.

The brand has also been cited as the Top 2 fastest-growing restaurant brand in the world. Surging by an impressive 51% to USD2.3 billion in brand value, Jollibee ascended from rank 20 to rank 17 in this year’s Global Restaurant Rankings.

Jollibee continues to gain strong traction among mainstream consumers in countries outside the Philippines. In Vietnam and Brunei, mainstream non-Filipino locals comprise about 100% of customers; 81% in Malaysia; 80% in the United Kingdom; 70% in Singapore; and 60% in Hong Kong. This is a testament to the brand’s global appeal.

Jollibee Group flagship brands in the ranking

Another Jollibee Group-owned brand, The Coffee Bean and Tea Leaf ®, has also been included in the Top 10 Brands for Customer Satisfaction in Kuwait. It also emerged as the top brand in the café category. CBTL is Jollibee Group’s flagship brand for the coffee and tea business.

Hashtag: #Jollibee 

The issuer is solely responsible for the content of this announcement.

About Jollibee Group

Jollibee Foods Corporation (JFC, also known as Jollibee Group) is one of the fastest-growing restaurant companies in the world. Its mission is to serve great-tasting food and bring the joy of eating to everyone through its 18 brands with over 6,900 stores across 33 countries.

The Jollibee Group has eight wholly owned brands (Jollibee, Chowking, Greenwich, Red Ribbon, Mang Inasal, Yonghe King, Hong Zhuang Yuan, Smashburger); four franchised brands (Burger King, Panda Express, and Yoshinoya in the Philippines, and Tim Ho Wan in certain territories in China); 80% ownership of The Coffee Bean and Tea Leaf; 60% ownership in the SuperFoods Group that owns Highlands Coffee; and 51% ownership of Milksha, a popular Taiwanese bubble tea brand. JFC also has a business venture with award-winning Chef Rick Bayless for Tortazo, a Mexican fast-casual restaurant business in the United States.

The Jollibee Group, through its subsidiary Jollibee Worldwide Pte. Ltd. (JWPL) owns 92% participating interest in Titan Dining LP, a private equity fund that owns the Tim Ho Wan brand. The Jollibee Group has a joint venture with the THW Group to open and operate THW restaurants in Mainland China. The Company also established a joint venture company that will own and operate Tiong Bahru Bakery and Common Man Coffee Roasters in the Philippines. Recently, the Jollibee Group signed agreements to own 10% ownership in Botrista, a leader in the beverage technology space. The Company also owns a 90% participating interest in Titan Dining Partners II Ltd to further grow Asia Pacific food service brands and/or bring strong global food service brands to Asia Pacific.

The Jollibee Group has launched its global sustainability agenda dubbed Joy for Tomorrow, which aims to strengthen the Company’s commitment to sustainable business practices. The agenda centers on the key pillars of Food, People, and Planet, and consists of 10 focus areas namely: food safety, food quality, nutrition & transparency, employee welfare, farmers livelihood, community support, good governance, packaging & recycling, waste reduction, and energy & water efficiency. Each focus area sets goals and initiatives that contribute and align with the United Nations Sustainable Development Goals (UN SDGs (Sustainable Development Goals)).

The Jollibee Group was named the Philippines’ Most Admired Company by the Asian Wall Street Journal for ten years. It was also honored as one of Asia’s Fab 50 Companies and among the World’s Best Employers and World’s Top Female-Friendly Companies by Forbes. The Company is also a three-time recipient of Gallup’s Exceptional Workplace Award and was recently cited in TIME’s List of the World’s Best Companies.

To learn more about Jollibee Group, visit www.jollibeegroup.com

Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries

New sponsored testing program leverages Myriad’s MyChoice Tests for patients with high-grade serous ovarian cancer

SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients. A new sponsored testing program leveraging Myriad’s MyChoice HRD Plus and MyChoice CDx Plus Tests (collectively referred to as Myriad’s MyChoice Tests) is now available in Argentina, Brazil, Chile, Colombia, Egypt, Netherlands, Saudia Arabia, Singapore, and United Arab Emirates.

HRD testing is an important predictive and prognostic biomarker for patients who have ovarian cancer. Myriad’s MyChoice Tests determine HRD status in women with ovarian cancer. Clinicians can order this test through their local pathology labs and samples are sent to Myriad Genetics.

This collaboration delivers on both companies’ shared commitment to improve care for patients with advanced ovarian cancer by facilitating access to genetic testing and demonstrates a mutual dedication to meeting an unmet need for patients who otherwise may not have access to testing.

“Our collaboration with GSK is an important step forward in providing critical genetic insights that can help clinicians guide more personalized ovarian cancer treatment decisions,” said Patrick Burke, PhD, EVP of Strategy and Innovation, Myriad Genetics. “In the pursuit of advancing healthcare equity, Myriad is committed to extending the reach of our diagnostic solutions, like Myriad’s MyChoice Tests into additional markets to support more targeted patient care based on their genomic profile.”

About Myriad’s MyChoice Test
Myriad’s MyChoice® test is the most comprehensive tumor test for determining HRD status based on the assessment of genomic alterations in genes such as BRCA1 and BRCA2 and Genomic Instability Score (GIS) status using Myriad’s proprietary algorithm.  It enables healthcare professionals to identify patients with advanced ovarian cancer who are more likely to respond to treatment with targeted therapies.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that this collaboration will increase access to HRD testing and can help clinicians guide more personalized ovarian cancer treatment decisions for patients. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com

Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com

GlobeNewswire Distribution ID 9151576